Melinta Therapeutics, Inc. and Cempra, Inc. announced that their joint chief executive officer (CEO) selection committee has selected Dan Wechsler to be president and CEO and a member of the board of directors of the combined company. Most recently, Mr. Wechsler served as president and CEO of Smile Brands, Inc. until its sale in 2016, at which time he joined Welsh, Carson, Anderson & Stowe as an operating partner. Wechsler's appointment as president and CEO is subject to and effective upon the closing of the merger between Melinta and Cempra.

Mr. Wechsler's appointment as a member of the board of directors of the combined company is subject to the closing of the merger and will be effective ten days following the filing of the supplemental information statement on Schedule 14f-1 relating to Mr. Wechsler. As previously announced, the Cempra shareholder vote on the merger is scheduled for November 3, 2017 and the parties expect to close the merger as promptly as practicable thereafter. The combined company will keep the name Melinta Therapeutics upon the closing of the merger.